RxDoctor Payments Data

Laura Quinnette

Medical · Council Bluffs, IANPI 1922458959

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 825 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 57 manufacturers, the largest accounting for just 11.6% — the pattern of someone who eats at a lot of different presentations. Among medical clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$13,531in general payments, 2019–2025

Across 825 payments — averaging $16.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$2K
  • AbbVie$1K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Gilead$781
  • Amgen$753
  • plus $7K from 51 others

What the payments were for

  • Food & beverage$13,42399%
  • Education$1071%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,531 in reported general payments places this provider in the 95th percentile of 141 medical providers in Iowa.

See all medical providers in Iowa

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter70$62,824
FarxigaDapagliflozin Propanediol48$43,518
TrulicityDulaglutide41$40,326
JardianceEmpagliflozin50$38,848
MounjaroTirzepatide29$35,159
Breztri AerosphereBudesonide/Glycopyr/Formoterol35$30,139
LinzessLinaclotide49$27,265
OzempicSemaglutide23$22,661
GemtesaVibegron22$17,578
XareltoRivaroxaban23$15,997
RybelsusSemaglutide13$15,698
KerendiaFinerenone16$12,746
Varenicline Tartrate19$6,170
Advair HfaFluticasone Propion/Salmeterol11$3,648
Albuterol Sulfate HfaAlbuterol Sulfate110$2,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$1,574$75,48570 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,241$73,65783 claims
GSKTrelegy Ellipta$539$62,82470 claims
Boehringer IngelheimJardiance$181$38,84850 claims
Novo NordiskOzempic, Rybelsus$1,069$38,35936 claims
AbbVieLinzess$1,408$27,26549 claims
Sumitomo Pharma America, Inc.Gemtesa$188$17,57822 claims
Johnson & JohnsonXarelto$385$15,99723 claims
BayerKerendia$520$12,74616 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 141 medical providers in Iowa.

Other medical in Council Bluffs

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →